Treprostinil-13C2-d1 (Sodium)

Treprostinil-13C2-d1 (Sodium) (UT-15-13C2-d1 (sodium) ) is deuterium and 13C labeled Treprostinil (sodium) . Treprostinil (UT-15) sodium is a potent DP1 and EP2 agonist with EC50 values of 0.6±0.1 and 6.2±1.2 nM, respectively.

Product Specifications

Product Name Alternative

UT-15-13C2-d1 (sodium)

UNSPSC

12352005

Target

Isotope-Labeled Compounds; Prostaglandin Receptor

Related Pathways

GPCR/G Protein; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Inflammation/Immunology; Endocrinology

Smiles

CCCCC[C@H](O)CC[C@@H]1[C@]2([H])[C@@](C[C@@]1([2H])O)([H])CC3=C(O[13C][13C](O[Na])=O)C=CC=C3C2

Molecular Formula

C21 13C2H30DNaO5

Molecular Weight

413.47

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Whittle BJ, et al. Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist. Biochem Pharmacol. 2012 Jul 1;84 (1) :68-75.|[3]Ferrantino M, et al. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2011 Nov;12 (16) :2583-93.|[4]Ghonem N, et al. Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. Am J Transplant. 2011 Nov;11 (11) :2508-16.|[5]Smadja DM, et al. Treprostinil indirectly regulates endothelial colony forming cell angiogenic properties by increasing VEGF-A produced by mesenchymal stem cells. Thromb Haemost. 2015 Oct;114 (4) :735-47.|[6]Kazemi Z, et al. Repurposing Treprostinil for Enhancing Hematopoietic Progenitor Cell Transplantation. Mol Pharmacol. 2016 Jun;89 (6) :630-44.|[7]Nikam VS, et al. Treprostinil inhibits the recruitment of bone marrow-derived circulating fibrocytes in chronic hypoxic pulmonary hypertension. Eur Respir J. 2010 Dec;36 (6) :1302-14.